Program
pegfilgrastim
Also written as “Pegfilgrastim”, “CHS-1701” and “QL0605(PEG-rhG-CSF)”.
Its studies are mostly in Neutropenia · Breast Neoplasms · Lymphoma, Non-Hodgkin · Lymphoma · Febrile Neutropenia, led by 21 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 150 open or running | phase 4since Jun 21, 2005 | May 3, 2002 | none ahead |
| Dong-A ST | 30 open or running | phase 3since Jan 19, 2012 | Jan 19, 2012 | none ahead |
| Kyowa Kirin | 30 open or running | phase 2since Aug 14, 2006 | Aug 14, 2006 | none ahead |
| Adello Biologics | 20 open or running | phase 1since Apr 12, 2017 | Apr 12, 2017 | none ahead |
| coherus-biosciences-inc | 20 open or running | phase 1since Apr 8, 2015 | Apr 8, 2015 | none ahead |
| Fresenius Kabi | 20 open or running | phase 1since Aug 14, 2017 | Aug 14, 2017 | none ahead |
| hangzhou-jiuyuan-gene-engineering-co-ltd | 20 open or running | phase 2since Aug 6, 2013 | Jul 2, 2012 | none ahead |
| Intas Pharmaceuticals | 20 open or running | phase 1since Jul 8, 2019 | Jul 8, 2019 | none ahead |
| Merckle | 20 open or running | phase 1since Apr 18, 2012 | Apr 18, 2012 | none ahead |
| Mundipharma | 20 open or running | phase 1since Dec 10, 2015 | Dec 10, 2015 | none ahead |
| Qilu Pharmaceutical | 21 open or running | phase 4since Sep 25, 2024 | Nov 9, 2020 | none ahead |
| Amneal Pharmaceuticals | 10 open or running | phase 1since Feb 6, 2026 | Feb 6, 2026 | none ahead |
| coherus-oncology-inc | 10 open or running | phase 1since Mar 2, 2015 | Mar 2, 2015 | none ahead |
| Eurofarma Laboratorios | 10 open or running | phase 1since Oct 20, 2015 | Oct 20, 2015 | none ahead |
| GC Biopharma | 10 open or running | phase 3since Feb 6, 2011 | Feb 6, 2011 | none ahead |
| gedeon-richter-plc | 10 open or running | phase 1since Apr 26, 2017 | Apr 26, 2017 | none ahead |
| gema-biotech-s-a | 10 open or running | phase 3since Feb 15, 2016 | Feb 15, 2016 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 4since May 16, 2016 | May 16, 2016 | none ahead |
| kexing-biopharm-co-ltd | 11 open or running | phase 3since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| nanogen-pharmaceutical-biotechnology-joint-stock-company | 10 open or running | phase 1since Dec 12, 2017 | Dec 12, 2017 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 3since Jan 21, 2014 | Jan 21, 2014 | none ahead |
Also a collaborator on its studies: lambda-therapeutic-research-ltd, celerion and symyoo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 30 studies since May 3, 2002.
- May 16, 2016Hoffmann-La Roche's first study: phase 4 study in Lymphoma, Non-HodgkinNew to Hoffmann-La RocheHoffmann-La Roche · NCT02782845 · 53 enrolled · Colombia, Mexico
- Sep 19, 2016Phase 1 study in Healthy VolunteersMundipharma · NCT02912377 · 96 enrolled · Germany
- Oct 13, 2016Phase 1 study in LymphomaDong-A ST · NCT02963389 · 27 enrolled · Korea, Republic of
- Apr 12, 2017Adello Biologics's first studies: 2 phase 1 studies in Healthy VolunteersNew to Adello BiologicsAdello Biologics · NCT03206229, NCT03202927
- Apr 26, 2017gedeon-richter-plc's first study: phase 1 study in BioequivalenceNew to gedeon-richter-plcgedeon-richter-plc · NCT03146988 · 150 enrolled · United Kingdom
- Aug 14, 2017Fresenius Kabi's first studies: 2 phase 1 studies in HealthyNew to Fresenius KabiFresenius Kabi · NCT03251248, NCT03251339
- Dec 12, 2017nanogen-pharmaceutical-biotechnology-joint-stock-company's first study: phase 1 study in Breast NeoplasmsNew to nanogen-pharmaceutical-biotechnology-joint-stock-companynanogen-pharmaceutical-biotechnology-joint-stock-company · NCT03376503 · 24 enrolled · Vietnam
- May 23, 2019Phase 2 study in Peripheral Blood Stem Cell TransplantationKyowa Kirin · NCT03993639 · 35 enrolled · Japan
- Jul 8, 2019Intas Pharmaceuticals's first studies: 2 phase 1 studiesNew to Intas PharmaceuticalsIntas Pharmaceuticals · NCT04015232, NCT04014062
- Nov 9, 2020Qilu Pharmaceutical's first study: phase 1 study in HealthyNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT04651036 · 300 enrolled · Germany, United Kingdom
- Aug 2, 2021Phase 2 study in Multiple MyelomaKyowa Kirin · NCT05007652 · 64 enrolled · Japan
- Sep 25, 2024Phase 4 study in Chemotherapy-Induced Febrile NeutropeniaQilu Pharmaceutical · NCT06616571 · 336 planned · China
- Nov 25, 2024kexing-biopharm-co-ltd's first study: phase 3 study in Chemotherapy-Induced Febrile NeutropeniaNew to kexing-biopharm-co-ltdkexing-biopharm-co-ltd · NCT06711523 · 250 enrolled · China
- Feb 6, 2026Amneal Pharmaceuticals's first study: phase 1 study in Healthy VolunteerNew to Amneal PharmaceuticalsAmneal Pharmaceuticals · NCT07416955 · 180 enrolled · United States
TargetBeta
“A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity”NCIt, by rule
“Granulocyte colony stimulating factor receptor agonist”ChEMBL 37, by rule
Studies
All 47 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07416955Healthy Volunteer · United States | 1 | Completed | Amneal Pharmaceuticals | Oct 10, 2025 | 180 |
| NCT06711523Chemotherapy-Induced Febrile Neutropenia · China | 3 | Active, not recruiting | kexing-biopharm-co-ltd | Jun 30, 2026 | 250 |
| NCT06616571Chemotherapy-Induced Febrile Neutropenia · China | 4 | Recruiting | Qilu Pharmaceutical | Dec 30, 2025 | 336 |
| NCT05007652Multiple Myeloma · Japan | 2 | Completed | Kyowa Kirin | Oct 25, 2022 | 64 |
| NCT04651036Healthy · Germany, United Kingdom | 1 | UNKNOWN | Qilu Pharmaceutical | Nov 30, 2021 | 300 |
| NCT04015232Immunogenicity · India | 1 | Completed | Intas Pharmaceuticals | Jun 5, 2018 | 200 |
| NCT04014062Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers · India | 1 | Completed | Intas Pharmaceuticals | May 1, 2018 | 144 |
| NCT03993639Peripheral Blood Stem Cell Transplantation · Japan | 2 | Completed | Kyowa Kirin | Jul 21, 2020 | 35 |
| NCT03376503Breast Neoplasms · Vietnam | 1 | Completed | nanogen-pharmaceutical-biotechnology-joint-stock-company | Oct 9, 2017 | 24 |
| NCT03251339Healthy · New Zealand | 1 | Completed | Fresenius Kabi | Feb 5, 2018 | 336 |
| NCT03251248Healthy · Australia | 1 | Completed | Fresenius Kabi | May 8, 2018 | 294 |
| NCT03146988Bioequivalence · United Kingdom | 1 | Completed | gedeon-richter-plc | Sep 14, 2017 | 150 |
| NCT03202927Healthy Volunteers · United States | 1 | Completed | Adello Biologics | Mar 1, 2018 | 102 |
| NCT03206229Healthy Volunteers · United States | 1 | Completed | Adello Biologics | Jun 2, 2017 | 120 |
| NCT02963389Lymphoma · Korea, Republic of | 1 | Completed | Dong-A ST | Nov 2018 | 27 |
| NCT02912377Healthy Volunteers · Germany | 1 | Completed | Mundipharma | May 2017 | 96 |
| NCT02782845Lymphoma, Non-Hodgkin · Colombia, Mexico | 4 | Completed | Hoffmann-La Roche | Oct 2007 | 53 |
| NCT03404752Breast Neoplasms · Argentina | 3 | UNKNOWN | gema-biotech-s-a | Jun 2018 | 120 |
| NCT02650973Healthy · United States | 1 | Completed | coherus-biosciences-inc | Jun 2016 | 122 |
| NCT02629562Clinical Pharmacology · Germany | 1 | Completed | Mundipharma | Jul 2016 | 172 |
| NCT02589301Neutropenia · Brazil | 1 | Completed | Eurofarma Laboratorios | Mar 2016 | 100 |
| NCT02418104Immunity, Humoral · United States | 1 | Completed | coherus-biosciences-inc | Dec 2015 | 303 |
| NCT02385851Bioequivalence · United States | 1 | Completed | coherus-oncology-inc | Jul 2015 | 116 |
| NCT02306915Pharmacokinetics · United Kingdom | 1 | Completed | Merckle | Mar 2015 | 48 |
| NCT02044276Neutropenia · Germany, Italy, Spain | 3 | Completed | Teva Pharmaceutical Industries | Aug 29, 2017 | 101 |
| NCT01923545Chemotherapy Induced Neutropenia · Korea, Republic of | 2 | Completed | Dong-A ST | May 2011 | 61 |
| NCT01918241Neutropenia · China | 2 | UNKNOWN | hangzhou-jiuyuan-gene-engineering-co-ltd | Jan 2016 | 200 |
| NCT01637493Neutropenia · China | 1 | UNKNOWN | hangzhou-jiuyuan-gene-engineering-co-ltd | Feb 2013 | 24 |
| NCT01585649Neuroectodermal Tumors, Primitive, Peripheral · Bulgaria, Czech Republic, Hungary and more | 1 | Completed | Merckle | Jun 2014 | 21 |
| NCT01674855Chemotherapy Induced Neutropenia · Korea, Republic of | 3 | Completed | Dong-A ST | Feb 2013 | 74 |
| NCT01328938Neutropenia · Korea, Republic of | 3 | Completed | GC Biopharma | Nov 2012 | 177 |
| NCT00364468Neutropenia · Japan | 2 | Completed | Kyowa Kirin | Mar 2008 | 107 |
| NCT00277160Neutropenia | 4 | Completed | Amgen | Nov 2004 | 852 |
| NCT00261313Breast Neoplasms | 2 | Completed | Amgen | Jun 2007 | 80 |
| NCT00124111Breast Neoplasms | 2 | Completed | Amgen | ||
| NCT00117910Breast Neoplasms | 3 | Completed | Amgen | ||
| NCT00117897Lymphoma, Non-Hodgkin | 2 | Completed | Amgen | ||
| NCT00117455Lymphoma, Non-Hodgkin | 2 | Completed | Amgen | ||
| NCT00117442Breast Neoplasms | 2 | Completed | Amgen | Aug 2004 | 61 |
| NCT00115414Breast Neoplasms | 2 | Completed | Amgen | ||
| NCT00115206Carcinoma, Non-Small-Cell Lung | 4 | Completed | Amgen | ||
| NCT00115193Lymphoma, Non-Hodgkin | 2 | Completed | Amgen | Aug 2005 | 77 |
| NCT00114764Leukemia, Myeloid | 2 | Completed | Amgen | Apr 2004 | 84 |
| NCT00094809Colonic Neoplasms | 2 | Completed | Amgen | May 19, 2006 | 252 |
| NCT00066092Lymphoma | 2 | Completed | Amgen | Mar 2004 | 41 |
| NCT00035620Sarcoma | 2 | Completed | Amgen | Jan 2007 | 44 |
| NCT00035594Neutropenia | 3 | Completed | Amgen | Feb 2004 | 928 |
How it is read
Names in the registry
- “Pegfilgrastim”, 13 entries
- “pegfilgrastim”, 12 entries
- “CHS-1701”, 3 entries
- “QL0605(PEG-rhG-CSF)”, 2 entries
- “lipegfilgrastim”, 2 entries
Codes read as this program: TPI120.
Conditions, from the studies’ own filings
- Neutropenia, 14 studies
- Breast Neoplasms, 8 studies
- Lymphoma, Non-Hodgkin, 4 studies
- Lymphoma, 2 studies
- Febrile Neutropenia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.